Centessa Pharmaceuticals (CNTA) CBO sells 73,196 shares in planned trades

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Centessa Pharmaceuticals Chief Business Officer Gregory M. Weinhoff sold 73,196 Ordinary Shares of CNTA in open-market transactions. The sales occurred on March 13, 2026 at weighted average prices of $26.1668 and $27.1570 per share across multiple trades within disclosed price ranges.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, indicating they were scheduled in advance. Following these sales, Weinhoff continues to hold 65,925 Ordinary Shares directly.

Insider Trade Summary 10b5-1

Net Seller: 73,196 shares ($1,927,131)

Net Sell 2 txns

Insider Weinhoff Gregory M

Role Chief Business Officer

Sold 73,196 shs ($1.93M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	61,253	$26.1668	$1.60M
Sale	Ordinary Shares	11,943	$27.157	$324K

Holdings After Transaction: Ordinary Shares — 77,868 shares (Direct)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/13/2026 - 06:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weinhoff Gregory M

(Last)

(First)

(Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE

WA14 2DT

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	03/13/2026		S⁽²⁾		61,253	D	$26.1668⁽³⁾	77,868	D
Ordinary Shares⁽¹⁾	03/13/2026		S⁽²⁾		11,943	D	$27.157⁽⁴⁾	65,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Raphael Deferiere, attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CNTA report for Gregory M. Weinhoff?

Centessa Pharmaceuticals reported that Chief Business Officer Gregory M. Weinhoff sold 73,196 Ordinary Shares. The sales occurred on March 13, 2026, in two open-market transactions at weighted average prices of $26.1668 and $27.1570 per share across multiple individual trades.

At what prices did the CNTA insider shares sell in this Form 4?

The reported CNTA insider sales occurred at weighted average prices of $26.1668 and $27.1570 per share. Underlying trades were executed in ranges of $25.75–$26.70 and $26.805–$27.445, with full price breakdowns available on request from the issuer or the reporting person.

Was the CNTA insider sale by Gregory Weinhoff under a Rule 10b5-1 plan?

Yes. The filing states the CNTA share sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Gregory M. Weinhoff on November 12, 2025. Such plans schedule trades in advance, reducing the significance of trade timing as an indicator of insider sentiment.

How many Centessa Pharmaceuticals (CNTA) shares does the insider hold after the sale?

After the reported open-market sales, Gregory M. Weinhoff holds 65,925 Ordinary Shares of Centessa Pharmaceuticals directly. This post-transaction holding figure comes from the Form 4’s ownership column, which reflects his remaining direct position following the March 13, 2026 transactions.

How many CNTA shares in total were sold in this Form 4 filing?

The Form 4 shows aggregate sales of 73,196 Centessa Pharmaceuticals Ordinary Shares by Gregory M. Weinhoff. This total combines 61,253 shares sold at a weighted average price of $26.1668 and 11,943 shares sold at a weighted average price of $27.1570.

Are Centessa Pharmaceuticals (CNTA) Ordinary Shares represented by ADSs?

Yes. The filing notes that Centessa Pharmaceuticals Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share. This one-to-one relationship helps U.S. investors trade the company’s equity more easily on U.S. markets.